公开(公告)号：US20240293565A1

公开(公告)日：2024-09-05

申请号：US18570403

申请日：2022-06-15

申请人： BEIJING SINOTAU BIO-PHARMACEUTICALS TECHNOLOGY CO., LTD.

发明人： Xiaoyan ZHONG ,  Zhe Li ,  Jie ZHU

IPC分类号： A61K47/68 ,  A61K35/00 ,  C07K16/32

CPC分类号： A61K47/68031 ,  A61K35/00 ,  A61K47/6849 ,  A61K47/6889 ,  C07K16/32 ,  C07K2317/24 ,  C07K2317/565 ,  C07K2317/76

摘要： Provided is an anti-HER3 antibody, or an antibody drug conjugate (ADC) containing the anti-HER3 antibody. Also provided is the use of the antibody or ADC in the treatment of HER3-expression cancers.

公开(公告)号：US20230112450A1

公开(公告)日：2023-04-13

申请号：US17909658

申请日：2021-03-05

申请人： Beijing Sinotau Bio-Pharmaceuticals Technology Co., Ltd.

发明人： Xiaoyan ZHONG ,  Fengqi CAO ,  Zhe LI

IPC分类号： A61K31/5025 ,  A61K38/19 ,  A61K39/395 ,  A61P35/00 ,  A61P11/00

摘要： Provided herein are a combination of antitumor medicaments comprising a TRAIL-R2 agonistic antibody (e.g., CTB006) and Ponatinib or its hydrochloride. Also provided herein are a method of treating tumors that include administering therapeutically effective amounts of a TRAIL-R2 agonistic antibody and Ponatinib or its hydrochloride to a patient. The synergistic effect of these two medicaments helps to enhance the effect of tumor treatment.